Evidence map›Paper›PMID 35115343›Full record

ArticleThe European respiratory journal2022

Methodological caveats regarding "Novel insights into surfactant protein C trafficking revealed through the study of a pathogenic mutant".

Surafel Mulugeta, Timothy E Weaver, Michael F Beers

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Surafel MulugetaPulmonary, Allergy, and Critical Care Division, Dept of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA mulugeta@pennmedicine.upenn.edu.ORCID 0000-0002-8734-8688
Timothy E WeaverCincinnati Children's Hospital Medical Center, Division of Pulmonary Biology, Cincinnati, OH, USA.
Michael F BeersPulmonary, Allergy, and Critical Care Division, Dept of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Funding

Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary FibrosisU01HL152970 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BEERS, MICHAEL FRANCIS · 2021 to 2024
$3.0M
Biosynthesis and Trafficking of Surfactant Protein C In Health and DiseaseR01HL119436 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BEERS, MICHAEL FRANCIS · 2013 to 2017
$2.0M
NHLBI NIH HHS R01 HL119436NHLBI NIH HHS U01 HL152970
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Protein CSurface-Active AgentsHumansMutationProtein CSurface-Active Agents

Identifiers

PMID35115343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.